… Hydroxyurea is a cytostatic agent that is also found … benefits in SCD patients experiencing
acute vaso-occlusive pain; … the NO-mediated acute beneficial effects of hydroxyurea in the …

… use of hydroxyurea are sought to further reduce vaso-occlusive … These agents significantly
reduced stimulated human SCA … and abrogation of vaso-occlusive events are a goal for …

… acute intravenous HC administration in mice abolishes haemolysis- induced systemic
inflammation via NO pathway activation, implying potential benefits … 1– 2 events occurred in each …

… with many events subsequent … agents blocking their action are in preclinical and early
clinical studies. Whether a newer fetal hemoglobin enhancer will supplant the use of hydroxyurea, …

… The phase III Multicenter Study of Hydroxyurea (MSH study) … Inflammation is a key step in
the cascade of events leading to … cGMP-amplifying agents have been shown to intensify the …

… cGMP-induced effects are regulated by endogenous receptor ligands such as nitric oxide (…
established that PKG-I may also be activated by oxidizing agents such as hydrogen peroxide. …

… In this review, we discuss the challenges associated with hydroxyurea treatment. … Hydroxyurea
and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in …

… effects on vaso-occlusive mechanisms and survival.92 That same group also showed that
acutely, hydroxyurea … -9) and cGMP amplifying agents are currently under various stages of …

… and chronic organ dysfunction from repeated sickling events … It is an antineoplastic and
myelosuppressive agent also used to … How hydroxyurea prevents vaso-occlusive episodes in …

… we individually examined hydroxyurea’s (NO releasing agent) … We examine the effects of the
NO dependence in hydroxyurea … as to a reduction in inflammation and vaso-occlusive crisis. …